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Abstract: Glomerulonephritis [GN] is one of the common acquired pediatric renal disorders encountered in clinical 
practice. The clinical manifestations include gross or microscopic hematuria, proteinuria, and nephrotic syndrome. Renal 
dysfunction and hypertension may also be present in many patients. Etiopathogenesis of GN can be idiopathic in a large 
majority, while some may result from infections or known immune disorders. Several of these disorders are now believed 
to arise from dysfunctions of podocytes and are grouped under the heading of “podocytopathies”. This review focuses on 
the clinical manifestations and management of the common forms of acute GN encountered in children. 
Keywords: Acute post-streptococcal glomerulonephritis, Glomerulonephritis, Henoch-Schönlein purpura, IgA nephropathy, 
lupus nephritis. 
INTRODUCTION 
 In the pre-renal biopsy era, most forms of nephritis and 
nephrotic syndrome were consdered as “Bright’s disease” 
[1]. With a better understanding of the pathology and 
pathogenesis of renal diseases, the term glomerulonephritis 
[GN] is used in the contemporary scientific literature to 
define non-infectious inflammatory lesion affecting the 
glomeruli. The clinical manifestations of GN encompass a 
spectrum that may include gross or microscopic hematuria, 
proteinuria, and nephrotic syndrome. Renal dysfunction and 
hypertension may also be present in many patients. 
Etiopathogenesis of GN also varies, being idiopathic in a 
large majority, while some may result from infections, such 
as hepatitis or human immunodeficiency virus-1 [HIV-1], or 
from known immune disorders, such as systemic lupus 
erythematosus [SLE]. 
CLASSIFICATION 
 From a clinical perspective, GN can be classified as acute 
or chronic (Table 1). A sub-group of patients with acute GN 
designated as “rapidly progressive GN” [RPGN] have an 
aggressive clinical presentation, progressive decline of renal 
function occurring over days to weeks, and presence of  
crescents around the glomerular tufts in renal biopsy. 
Chronic GN, on the other hand, has an indolent clinical 
course, usually presenting with proteinuria, nephrotic 
syndrome, hypertension and variable degree of renal 
dysfunction. Renal pathology in chronic GN is variable. Of 
course, some disorders overlap in classification, since they 
can cause both acute and chronic GN. This review will 
discuss common forms of acute GN seen in children. 
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ACUTE POST-STREPTOCOCCAL GLOMERULONEPH-
RITIS 
 Acute post-streptococcal GN [APSGN] is the most 
common form of GN encountered in children. WHO 
estimates that 472,000 patients are affected globally with 
APSGN each year, and results in 5,000 deaths annually [2]. 
Most of the mortality is related to complications in the acute 
phase of the disease. 
Epidemiology 
 Although APSGN may occur at any age, it is more 
commonly encountered between the age of 2 and 15 years 
[3-5]. Occurrence of APSGN below the age of 2 years is rare 
[6]. A declining trend in APSGN has been well documented 
in the United States from early1960s, especially in the 
impetigo associated disease [7]. In a recent analysis of 
APSGN, Ilyas noted that the prevalence of the disease had 
decreased from 2.18/100,000 population in the 1959-1973 
cohort, to 0.64/100,000 in the 1999-2006 cohort [8]. 
ASPGN, however, remains a public health concern in 
developing countries, especially in the tropical regions [9]. 
APSGN follows upper respiratory or skin infection with 
group A β-hemolytic Streptococcus. Pharyngotonsillitis is a 
more common antecedent to APSGN in temperate climates 
and occurs during winter and spring months. Impetigo-
associated APSGN, on the other hand, is more common 
during summer and autumn months and occurs more 
frequently in the tropical regions [7-9]. 
Clinical Manifestations 
 The onset of APSGN usually occurs 7-14 days after 
pharyngotonsillitis, but can be longer in the impetigo-
associated disease [10]. Typical clinical features of APSGN 
consists of a combination of gross hematuria, oliguria, 
hypertension, mild lower extremity or periorbital edema, and 
a modest impairment in renal function (Fig. 1). Dull 
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abdominal pain or flank pain and malaise may be present [3, 
4, 10]. Mild fever can be seen in about half of the patients, 
often attributed to an underlying tonsillopharyngitis. Gross 
hematuria may last for a few weeks, but microscopic 
hematuria may persist for several months. 
 Hypertension is a common finding in patients with 
APSGN, occurring in over 80% of cases [4-6, 11]. Severe 
hypertension, hypertensive encephalopathy and 
radiographically defined posterior reversible encephalopathy 
syndrome [PRES] have also been reported [12]. Mild 
pretibial and periorbital edema, caused by fluid retention and 
oliguria are noted in most patients. Severe fluid overload and 
pulmonary edema may be seen in some (Fig. 2). 
Asymptomatic APSGN may occur in contacts or family 
members of index cases [13]. 
Pathogenesis 
 In the past, Streptococcal M antigen has been considered 
as the primary nephritogenic antigen involved in the 
Table 1. Classification of glomerulonephritis in children. 
 
Classification of Glomerulonephritis in Children 
 
1. Acute glomerulonephritis 
• Acute post-infectious glomerulonephritis 
 Post-streptococcal GN 
 GN of infective endocarditis 
 Shunt nephritis 
 
• Acute glomerulonephritis associated with systemic disorders 
Systemic lupus erythematosus 
Henoch-Schonlein purpura 
Microscopic polyangitis and other vasculitic disorders 
Wegener's granulomatosis 
Antiglomerular basement membrane [AntiGBM] antibody mediated glomerulonephritis [ Goodpasture 
syndrome] 
 
2. Chronic glomerulonephritis 
• Focal segmental glomerulosclerosis [FSGS] 
• Membranoproliferative glomerulonephritis [MPGN] 
• Membranous glomerulonephritis 
• Immunoglobulin A [IgA] glomerulonephritis or nephropathy 
 
3. Rapidly progressive glomerulonephritis 
• Anti-neutrophil cytoplasmic autoantibody [ANCA] associated crescentic glomerulonephritis 
• Immune complex mediated crescentic glomerulonephritis 
• Membranoproliferative glomerulonephritis [MPGN] 
• Post-sterptococcal glomerulonephritis 
• Immunoglobulin A [IgA] glomerulonephritis or nephropathy 
• Antiglomerular basement membrane [AntiGBM] antibody mediated glomerulonephritis [ Goodpasture syndrome] 
 
 
Fig. (1). Time course of clinical and laboratory manifestations of post-streptococcal glomerulonephritis. Reproduced with permission from: 
Clinical Pediatric Nephrology, 3rd edition. Kher K, Schnaper HW, Greenbaum LW [Editors]. Taylor and Francis, Oxford, UK. 
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glomerular inflammatory response in APSGN [14]. 
Available evidence, however, does not support the relevance 
of M antigen as a nephritogenic antigen [15]. Studies done in 
the last two decades have focused on two separate antigens, 
and possibly others which may be involved in the 
pathogenesis of APSGN. These antigens are: 1] nephritis-
associated plasmin receptor [NAPlr], and 2] streptococcal 
pyrogenic exotoxin B [SPeB]. Once deposited in the 
glomerulus, both of these antigens induce complement 
activation, and promote glomerular tissue injury, induce 
chemoattractants and inflammatory response in the 
mesangial and endocapillary sites [16-18]. 
 
Fig. (2). Chest X-ray of a patient with post-streptococcal 
glomerulonephritis showing pulmonary edema. He presented with 
difficulty in breathing, oliguria and “brownish urine”. 
Diagnosis 
 Apart from clinical features, the diagnosis of APSGN is 
established by : 1] demonstration of a rise of antibodies 
against streptococcal antigens, and 2] documenting a 
decrease in the serum complement C3. Two streptococcal 
antibodies that are commonly employed in the diagnosis are: 
a] anti-streptolysin O [ASO] titer, and b] anti-DNAse B 
antibody. ASO titer may not be significantly elevated in 
some patients early in the course of the disease and should be 
repeated to demonstrate a rising titer. ASO titers may remain 
low in patients with impetigo-associated APSGN. A 
decrease in serum complement C3 resulting from its 
consumption in APSGN is seen in the majority of patients 
early in the disease, and the decrease is profound in some 
patients. Complement C4 is usually normal but low levels 
have been noted in a minority of patients [19]. 
 Renal dysfunction, characterized by elevated blood urea 
nitrogen [ BUN], and serum creatinine are seen transiently. 
Hyperkalemia is common in most patients and can be severe 
in some. A rising serum creatinine level and worsening of 
oliguria may be indicators of RPGN. These patients warrant 
a diagnostic renal biopsy. 
Renal Biopsy 
 Renal biopsy is not necessary in most patients with 
APSGN. In patients with RPGN, the presence of significant 
proteinuria or non-resolving renal disease, a renal biopsy is 
an important diagnostic tool. The characteristic findings of 
APSGN on renal biopsy consist of cellular proliferation 
within the glomeruli, chiefly affecting the endothelial cells 
and mesangium. Polymorphonuclear infiltration within the 
inflamed glomeruli is also usually present. In cases with 
RPGN, extraglomerular proliferation and crescent formation 
are usually present. Immunofluorescence microscopy shows 
immune deposits consisting of immunoglobulin G [IgG], 
along with complement C3. Electron-microscopy 
demonstrates presence of large sub-epithelial electron dense 
deposits or humps (Fig. 3). 
Treatment 
 Most patients with APSGN respond well to conservative 
therapy consisting of: 1] fluid restriction, 2] sodium and 
potassium restriction, 3] treatment of fluid overload with 
diuretics, and 4] treatment of hypertension. Loop diuretics 
[furosemide] may also be helpful in decreasing serum 
potassium level in patients with mild hyperkalemia. 
Hyperkalemia may require treatment with potassium 
exchange resins [sodium polystyrene sulfonate, 
Kayexalate®]. Dialysis therapy may become necessary in 
 
Fig. (3). Electron microscopy of renal biopsy in a patient with post-sterptococcal glomerulonephritis. A characteristic large subepithelial 
electron dense deposit, or “hump” is seen [arrow]. 
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patients with severe renal dysfunction, hyperkalemia or fluid 
overload, especially those with RPGN. 
 If group A beta hemolytic streptococci [GABS] are 
documented in the throat culture, or from skin lesions, the 
patient should be treated with appropriate antibiotic therapy. 
Although antibiotic therapy does not alter the clinical course 
of APSGN, elimination of nephritogenic group A beta 
streptococci as a reservoir of infection is important from an 
epidemiological perspective and preventing spread of the 
infection in the community. Antibiotic therapy has been 
found to be particularly helpful in curtailing the spread of 
GABS in epidemics. 
Prognosis 
 Mortality of APSGN during the acute phase of the 
disease is well known and ~5000 deaths occur annually 
around the globe according to WHO estimates [2]. The 
mortality rate in developed countries has declined 
dramatically. Hadiwijaya et al. reported a mortality rate of 
5.2% in Indonesia, while none of the 220 patients reported in 
a recent Japanese study died [20, 21]. Mortality during the 
acute phase of the illness is usually due to complications, 
such as hyperkalemia, fluid overload, hypertensive 
emergencies and uremia. 
 Long-term prognosis of APSGN in children is excellent. 
Microscopic hematuria usually resolves in 3-6 months but 
may persist in a rare patient for as long as 4 years [21]. 
Proteinuria is usually transient in uncomplicated APSGN, 
and resolves in a 2-12 weeks in over 80% cases, and in 98% 
by the end of the first year [21]. Hypertension resolves in 
most patients within the first two weeks, and renal function 
normalizes around the same time. 
HENOCH-SCHÖNLEIN PURPURA NEPHRITIS 
 Henoch-Schönlein purpura [HSP] is a leukocytoclastic 
vasculitis characterized by rash, systemic manifestations and 
development of GN in some children. Most patients with GN 
present as an acute clinical disorder, although an occasional 
patient may develop chronic GN and nephrotic syndrome, 
with progressive decline in renal function. 
Epidemiology 
 The incidence of HSP has been estimated to be ~20.4 per 
100,000 population per year [22]. HSP primarily affects 
children younger than 10 years of age. Mean age at onset is 
~6 years with slight male preponderance, but the disease has 
been reported in children as young as 6 months of age [23, 
24]. The disease is more common in the fall and spring [23-
27]. Geographic clustering, or micro-epidemics have also 
been reported occasionally [28]. 
Pathogenesis 
 HSP and IgA nephropathy are now considered to be the 
two ends of the spectrum of the same disease. Some have 
gone so far as to characterize IgA nephropathy as HSP 
without rash [29]. This is based on the observation of similar 
renal pathology and immunofluorescence findings, as well as  
 
abnormalities in circulating serum IgA in both of these 
disorders. Pathogenesis of the HSP is discussed below in 
conjunction with IgA nephropathy. 
Clinical Manifestations 
 Patients with HSP often present with history of a 
prodrome, usually an upper respiratory infection, followed 
by onset of abdominal pain, joint pain and swelling. Ankles 
and knees are commonly affected, but other large joints may 
also be affected. The child’s primary complaint may be 
difficulty in walking. A typical rash consisting of palpable 
purpuric lesions, usually begins around the medial malleolus 
and spread towards buttocks (Fig. 4) [23]. Extensor surfaces 
of the arms, particularly around elbows as well as the trunk 
are also affected, but the face is usually spared. In a rare 
patient, the onset of rash may be delayed by several weeks or 
months in relation to gross hematuria or proteinuria. Scrotal 
edema may be severe and may mimic testicular torsion [30]. 
Resolution of clinical symptoms usually occurs within two 
weeks, and is often complete by 4 weeks. Recurrence of rash 
is common and has been noted in 40-50% of cases, 
especially with renal involvement. Recurrences commonly 
occur in the first six months after the initial onset of the 
disease [23, 31]. Less common manifestation include 
cerebritis, pancreatitis, and pulmonary hemorrhage [32-34]. 
 
Fig. (4). Characteristic rash in the lower extremities in a patient 
with Henoch-Schönlein purpura. Patient had mild nephritis, 
characterized by microscopic hematuria. 
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 Renal disease in HSP characterized by microscopic or 
gross hematuria, proteinuria and nephrotic syndrome, occurs 
in 30-40% cases [23, 33]. Of these, hematuria is the most 
common feature. Mild proteinuria occurs in about 25% of 
unselected cases [23]. Severe proteinuria, nephrotic 
syndrome or nephritic-nephrotic manifestations [hematuria, 
proteinuria, renal dysfunction] occur in 5-10% of patients, 
and indicates severe renal disease [23, 35]. These patients 
require close follow up and monitoring. 
Diagnosis 
 European League Against Rheumatism/ Paediatric 
Rheumatology International Trials Organisation/ Paediatric 
Rheumatology European Society has proposed the following 
criteria for diagnosis of HSP with the mandatory presence of 
purpura or petechiae with lower limb predominance, plus 
one of four criteria: [1] abdominal pain; [2] skin biopsy 
demonstrating IgA; [3] arthritis or arthralgia; and [4] renal 
involvement manifesting as microscopic or gross hematuria 
and proteinuria [36]. BUN and serum creatinine elevation 
may be seen in those with significant nephritis. Patients with 
severe HSP nephritis may present with the nephrotic 
syndrome. Serum complement C3 is usually normal, but may 
be decreased in some patients [23, 37]. Evidence of recent 
streptococcal infection may be seen in up to 20-30% cases 
[23]. 
 The presence of IgA in the skin biopsy of patients with 
HSP is well known, and has been recognized as a diagnostic 
criterion of vasculitis in this disorder [36, 38]. Indeed, a skin 
biopsy rather than a renal biopsy has been considered as an 
adequate diagnostic test in patients with HSP nephritis [39]. 
In most cases of HSP nephritis, however, a renal biopsy is 
not necessary. Patients with progressive proteinuria or 
progressive decrease in renal function should be referred to a 
pediatric nephrologist, and a renal biopsy should be 
considered. A rapidly increasing serum creatinine in these 
patients may be indicative of crescentic or RPGN. An early 
renal biopsy and institution of therapy is an important key to 
renal outcome in such patients. 
Treatment 
 Treatment of most patients with HSP is largely 
symptomatic and supportive. Non-steroidal anti-
inflammatory drugs [NSAID] may be used for relief of joint 
pain. Use of oral corticosteroids has been shown to be 
effective in ameliorating the symptoms of abdominal pain in 
HSP [40]. The prednisone dose is usually 1-2 mg/kg /day for 
1-2 weeks, and then tapered. 
 Evidence based data on management of HSP nephritis is 
scant. Corticosteroids have not been shown to be effective in 
preventing nephritis in double blind controlled trials [40]. 
However, in a meta-analysis of published literature [1956 to 
January 2007] corticosteroids were noted to reduce the odds 
of developing persistent renal disease [41]. Mild nephritis, 
characterized by hematuria and sub nephrotic proteinuria 
usually resolves on its own and does not require intense 
corticosteroid treatment or immunotherapy [42]. Urinary 
findings usually abate in 4-6 weeks in these patients. 
 Numerous studies have documented an adverse outcome 
of severe renal disease in HSP. Those with nephritic-
nephrotic clinical features, nephrotic syndrome, renal 
dysfunction, and hypertension at presentation are at an 
increased risk to develop chronic kidney disease [CKD ] and 
ESRD later on [43-48]. Treatment of this subset of children 
remains controversial. Data on the use and effectiveness of 
corticosteroids in these patients is unclear, since these have 
often been used in conjunction with other 
immunosuppressive agents [49]. 
 Addition of cyclophosphamide to corticosteroids has 
been reported to be beneficial in patients with severe HSP 
nephritis [50]. In contrast, Tarshih et al. conducted a 
randomized controlled trial of 28 patients with histologically 
severe HSP nephritis who were treated with 
cyclophosphamide orally at a dose of 90mg/m2/day for 42 
days [51]. Another 28 patients in the control group received 
only supportive care. Cyclophosphamide treatment did not 
improve the renal outcome of patients, as judged by 
incidence of CKD or ESRD. 
 Other immunosuppressive agents that have been used in 
the treatment of severe HSP nephritis include azathioprine 
and mycophenolate mofetil [MMF] [52-54]. The role of 
MMF in the treatment of HSP nephritis was encouraging in 
early studies [53, 54]. Du et al. used MMF in a dose of 20 to 
25 mg/kg per day in 12 children with severe HSP nephritis 
and nephrotic range proteinuria [ mean 5.6 grams per day] 
for 10-15 months [53]. After a mean follow up of 3.9 years, 
all patients were free of proteinuria and all had normal renal 
function. Similarly, cyclosporine has also been useful in 
inducing remission of proteinuria in HSP nephritis and 
severe proteinuria [55]. Although effective, cyclosporine A 
dependence has been noted in some of these patients. 
Rituximab has been shown to be effective in inducing 
remission of patients with severe HSP nephritis who were 
refractory to other therapies [56]. Role of plasmapheresis in 
HSP nephritis is unclear. Some small studies have shown an 
improvement in patients with HSP and cerebritis, but others 
have no clear benefit in HSP associated RPGN [57, 58]. 
Prognosis 
 The overall mortality of HSP nephritis is less than 1%, 
with most deaths occurring due to complications, such as 
hypertensive encephalopathy and systemic disease [35]. 
Although remission is common in many patients with HSP 
nephritis, residual renal disease can occur in a high 
proportion of children affected by this disease [35, 45]. In 64 
children with biopsy proven HSP nephritis, Schärer et al. 
demonstrated renal survival in 79%, but CKD, ESRD or 
death occurred in 21% of cases [35]. Of those with renal 
survival, 37% eventually had complete clinical remission, 
30% had minor urinary abnormalities [sub-nephrotic range 
proteinuria, no hypertension, normal renal function], and 
12% had active renal disease [high grade proteinuria, 
with/without hypertension]. Hematuria alone, without 
associated proteinuria has been noted to have excellent long 
term outcome [39]. In a review of 1133 children with HSP, 
Narchi [48] noted that CKD never developed in patients with 
normal urinalysis but was seen in 1.6% of those with isolated 
urinary abnormalities, and in 19.5% of those who developed 
nephritic or nephrotic syndrome. The authors recommended 
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follow up for 6 weeks after disease onset, since proteinuria 
can develop subsequent to the initial presentation. 
 Factors associated with poor renal outcome include: 1] 
high grade or nephrotic range proteinuria, 2] nephritic-
nephrotic presentation [proteinuria, hematuria, hypertension 
and renal dysfunction], 3] renal failure at initial presentation, 
and 4] severe renal biopsy changes, such as presence of 
crescents [35, 44-46, 59, 60]. Interestingly, in a large Turkish 
study of 179 children who underwent renal biopsy for HSP 
nephritis, no correlation was found between presence of 
crescents in the renal biopsy and long term outcome [61]. 
Renal outcome of HSP nephritis in adults, especially in 
females, has been noted to be worse than in children and 
males [47]. Recurrence of HSP nephritis in renal transplants 
has been reported, sometimes leading to graft loss [62]. 
IGA NEPHROPATHY 
 IgA nephropathy [IgAN], also known as Berger’s 
disease, was described as a distinct entity by Berger and 
Hinglais in 1968 in patients who had evidence of 
microscopic or gross hematuria as the dominant clinical 
manifestation [63]. IgAN now constitutes the commonest 
form of chronic GN in adults and accounts for about 50% of 
adults with CKD and ESRD world-wide [64, 65]. 
Epidemiology 
 The true incidence of IgAN is unclear. In the United 
States, IgAN accounts for ~10%, of all renal biopises [66]. In 
contrast, 20-35% of native kidney biopsies performed in 
Korea and Japan are diagnosed to have IgAN [67, 68]. South 
West Pediatric Nephrology group reported that 52% of 
children biopsied for gross hematuria carried the diagnosis of 
IgAN [69]. IgAN has been reported across all racial groups. 
One single center study reported that the incidence of IgAN 
may actually be higher among African American children in 
the United States [70]. Although not a familial disorder, 
large kindred of IgAN patients have been described in the 
United States and Italy [71, 72]. 
Clinical Manifestations 
 Patients with IgAN may present with dramatic symptoms 
of gross hematuria that follows an upper respiratory tract 
infection in the preceding 12-72 hours. This has often been 
labeled as “synpharyngetic hematuria” [73, 74]. Gross 
hematuria in APSGN, in contrast, occurs 10-14 days 
following a streptococcal URI. Gross hematuria usually lasts 
a few days, followed by microhematuria that can also vary in 
duration from few days to several weeks. Normal urinalysis 
may be seen in many patients with IgAGN. Proteinuria is 
usually seen early in the course of the disease. Nephrotic 
range proteinuria and nephrotic syndrome may be seen in 
patients with morphologically severe disease. Recurrent 
bouts of gross hematuria following URI are common in 
patients with IgAN, while persistent microhematuria may be 
a manifestation in about 50% of affected children. Clinical 
manifestations of IgAN in African American population 
conform to those seen in the Caucasian race [75]. 
 A secondary form of IgAN has been described in patients 
with liver disease, such as cirrhosis [76]. Gastrointestinal 
disorders, such as celiac disease and dermatitis herpetiformis 
are also known to be associated with IgAN [77, 78]. IgAN 
has also been reported in association with viral infections, 
such as HIV, and hepatitis A, B and C infections [79-82]. 
Pathogenesis 
 The pathogenesis of IgAN and HSP is not entirely clear. 
A ‘four hit” model for pathogenesis of IgAN has been 
proposed [83-85]. The first hit is a genetic predisposition to 
produce an abnormal IgA1 molecule in both of these 
disorders. Circulating IgA1produced by B cells in response 
to respiratory infection in patients with IgAN and HSP is 
deficient in galactose in the hinge region of the heavy chains. 
The second hit consists of developing autoantibodies against 
the abnormal galactose deficient-IgA1. These antibodies can 
be either IgG or IgA. The third hit consists of deposition of 
IgA1-antibody complexes in the glomerular mesangium, a 
process that is less well defined. The mesangial immune 
complexes may be developed in-situ or result from 
deposition of circulating immune complexes. The fourth hit 
is the initiation of inflammatory pathways and local 
activation of complement within the glomeruli, and release 
of cytokines in the glomerular tissues. It is this final pathway 
that leads to glomerular injury and inflammation [83-86]. 
 The pathogenesis of IgAN and HSP is believed to be 
similar, and the two disorders are believed to be the spectral 
ends of the same disorder. Some even go so far as to 
designate IgAN as “HSP without rash” [87, 88]. 
DIAGNOSIS 
 The diagnosis of IgAN requires a renal biopsy. However, 
during an initial discovery of microscopic hematuria, or first 
episode of gross hematuria, the diagnosis of APSGN needs 
to be ruled out (Table 2) by serum complement C3 level 
determination and evidence for GABS [ASO titer, anti-
DNAse B, throat culture]. Renal function tests, 
quantification of proteinuria by a 24- hour urine collection or 
first morning urine protein/creatinine ratio should also be 
assessed. Elevated levels of abnormal galactose-deficient 
IgA1 levels are noted in 70-80% of patients with IgAN [89]. 
However, this test may not be available commercially in 
most clinical laboratories. 
 Other conditions that present with gross hematuria, and 
need to be considered in the differential diagnosis include 
Alport syndrome, thin-basement membrane nephropathy 
[TBMN] and membranoproliferative GN [MPGN]. Systemic 
lupus nephritis also presents with gross or microscopic 
hematuria and proteinuria, and should be ruled out by 
appropriate laboratory evaluation. All of the above 
mentioned clinical conditions also need a renal biopsy for 
confirmation of the clinical diagnosis. 
Renal Biopsy 
 Renal biopsy findings in IgAN and HSP are similar; both 
disorders showing a variably increased mesangial matrix and 
cellularity on light microscopy. Immunofluorescence 
microscopy (Fig. 5) demonstrates a dominant presence of 
immunoglobulin A [IgA], along with complement C3 and 
IgG [74, 90]. 
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 The International IgA Nephropathy Network and the 
Renal Pathology Society has proposed Oxford classification 
of IgAN or Oxford -MEST classification [91, 92]. This renal 
biopsy classification utilizes the degree of mesangial 
cellularity, segmental glomerulosclerosis, endocapillary 
hypercellularity and tubulointerstitial fibrosis as the 
parameters of scoring (Table 3). The severity of renal biopsy 
is scored on a progressive scale of changes in each category, 
and the final score is indicated by a composite of each aspect 
of evaluation parameter. Although extraglomerular 
proliferation [crescent formation] is generally regarded as an 
indicator of poorer outcome in patients with GN, the Oxford 
classification of IgAN did not consider it to be an important 
variable in their study. In general, more severe morphologic 
disease correlates with a worse long-term outcome. 
Treatment 
 There is no clear consensus about treatment of IgAN. 
Since proteinuria is considered a marker of progression of 
renal disease in a variety of disorders, including IgAN, 
treatment with angiotensin converting enzyme inhibitors 
Table 2. Clinical features of acute glomerulonephritis associated with post-streptococcal disease, IgA nephropathy and Henoch-
Schonlein pupura. 
 
Clinical Parameters Acute Post-Streptococcal GN IgA GN HSP Nephritis 
Preceding URI  
Streptoccocal infection 10-14 days 
before onset of gross hematuria. 
Pyoderma associated APSGN: 
latent period may be up to 6 weeks 
24-72 hours before onset of 
hematuria [synpharyngetic]. URI is 
often viral in nature. 
May have preceding streptococcal 
infection. 
Streptococcal antibodies positive in 
25-30% 
Duration of hematuria 7-14 days 2-14 days. Recurrent gross hematuria with URI. 
Gross hematuria occurs in minority 
of patients. Microhematuria is more 
common 
Microhematuria Can persist up to 1 year Can persist, but may disappear in between gross hematuria. 
Microhematuria is common, usually 
resolves in few weeks. 
Serum complement C3 Low Normal Normal 
Other Clinical associations 
Hypertension 
Hyperkalemia 
Oliguria 
Mild azotemia 
Acute kidney injury 
Nephrotic syndrome 
Typical rash 
Joint pains 
Abdominal pain 
Risk for intessusception 
Renal Biopsy finding Sub-epithelial “humps” - electron dense deposits 
Mesangial cell and matrix 
proliferation 
Mesangial IgA, IgG and C3 
complement deposits 
Mesangial cell and matrix 
proliferation 
Mesangial IgA, IgG and C3 
complement deposits 
Prognosis Excellent Long-term risk of CKD and hypertension. 
Risk of CKD in only those with 
severe renal pathology. Most 
patients recover 
Abbreviations: CKD=chronic kidney disease; HSP=Henoch-Schonlein purpura; IgA= immunoglobulin A; IgG= immunoglobulin G. 
 
Fig. (5). Renal biopsy findings in patients with Henoch Schölnlein purpura nephritis and IgA nephropathy. (A) Light microscopy showing 
moderate mesangial cell and matrix increase. Glomerular capillary loops are otherwise open. There is no evidence of extraglomerular 
crescents in this case. (B). Immunofluorescence staining with IgA antibody, showing IgA immune deposits in the mesangial region. 
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[ACEI] should be considered in IgAN patients with 
significant or advancing proteinuria. Both ACEI and 
angiotensin receptor blockers [ARB] have been found to be 
useful in ameliorating proteinuria in children with IgAN [93, 
94]. 
Table 3. Oxford classification of renal biopsy scores in IgA 
nephropathy. Based on and modified from :Working 
Group of the International IgA Nephropathy 
Network and the Renal Pathology SocietyThe 
Oxford classification of IgA nephropathy: rationale, 
clinicopathological correlations, and classification. 
Kidney Int. 2009; 76: 534-45. 
 
Morphologic Findings Definition Score 
Mesangial cellularity [M] 
 
 
Segmental sclerosis [S] 
 
 
Endocapillary hypercellularity [E] 
 
 
Tubulointerstitial atrophy/ 
Fibrosis [T] 
< 50% mesangial tufts with ≥ 3 cells 
> 50% mesangial tufts with ≥ 3 cells 
 
Absent 
Present 
 
Absent 
Present 
 
0-25% cortical area 
26-50% cortical area 
>50% cortical 
M0 
M1 
 
S0 
S1 
 
E0 
E1 
 
T0 
T1 
T2 
 
 Corticosteroids alone may help patients with moderately 
severe disease. However, randomized controlled trials using 
corticosteroids alone in IgAN are limited. The South West 
Pediatric Nephrology group studied the effects of daily 
corticosteroid followed by alternate day therapy for a total of 
2 years in children and young adults with IgAN. This study 
did not demonstrate any superiority of treatment with 
corticosteroids over placebo in preventing decline of GFR 
[95]. A recent meta-analysis of published studies of IgA in 
adults and children demonstrated that corticosteroid use in 
IgAN was associated with a lower risk of renal disease and 
proteinuria in the follow up periods [96]. Further subgroup 
analysis of the data demonstrated that long term, low dose 
use of steroids did not reduce the risk of renal disease. On 
the other hand, high dose oral or intravenous costicosteroids 
used for a short time was helpful in reducing the long-term 
risk of renal disease in this analysis. 
 The role of MMF in the treatment of IgAN is unclear. 
Several studies have demonstrated failure of a clear benefit 
of MMF in the treatment of IgAN of varying severities [97, 
98]. Transient and partial remission of proteinuria has, 
however, been noted by some [98]. A metanalysis of MMF 
used in IgA nephropathy also did not demonstrate any 
benefit in the treatment of proteinuria or protecting decline in 
renal function [99]. In children with IgAN resistant to steroid 
therapy, combining corticosteroid treatment with MMF has 
been noted to be beneficial in inducing remission of 
proteinuria in 63% patients [100]. 
 Omega3 fatty supplements [fish oil] had been thought to 
be of benefit in ameliorating proteinuria in patients with 
IgAN [95]. The anti-proteinuric effect of omega-3 fatty acid 
therapy may be dose dependent [101]. A meta analysis of 
published data also suggested that despite ameliorating 
proteinuria, omega-3 fatty acids did not demonstrate any 
benefit in preventing a decline in renal function [102]. 
 Combining corticosteroids with other immunosupres-
sives, such as cyclophosphamide or azathioprine, alone or 
with warfarin and dipyridamole has been attempted 
[quadruple therapy]. In one such randomized controlled trial, 
azathioprine showed improvement in renal survival [103]. 
Because of the high risk for CKD in patients with severe 
renal pathology in patients with IgAN, most clinicians tend 
to use a combination of intravenous corticosteroids, and 
immunosupressives [azathioprine, MMF, cyclosporine]. 
Prognosis 
 IgAN has a better outcome in children than in adults. 
Japanese experience with IgAN suggests that spontaneous 
remission of hematuria is possible in ~50% of children with 
the disease [104, 105]. Time to remission of hematuria and 
proteinuria can be several years [5-6 years], and recurrence 
of symptoms after prolonged remissions is well known 
[105]. Persistent microscopic hematuria or recurrent gross 
hematuria occurs in 35% cases and widely spaced or isolated 
episodes of hematuria are present in 10-15% cases [73-75]. 
Frequency of gross hematuria or degree of microscopic 
hematuria do not predict long term prognosis [106]. On the 
other hand, the presence of proteinuria and its severity are 
well known to predict renal outcome in IgAN [107, 108]. 
Evolution of ESRD, often as adults, is seen in ~20-25% 
pediatric IgAN cases [73-75, 104, 109]. Finnish data 
suggests that ESRD occur in 11% cases, while 39% were 
being treated for hypertension and proteinuria after a mean 
follow up of 18.7 years [range: 8.5-29.8 years] [109]. 
Available data in adults also suggests that renal outcome is 
worse in those with the nephrotic syndrome [110]. The 
severity of histological changes on renal biopsy at onset, 
especially using the Oxford classification has also been 
shown to be predictive of outcome [111, 112]. 
LUPUS NEPHRITIS 
 Systemic lupus erythematosus [SLE] is an autoimmune 
disorder that is associated with GN and has a high potential 
for CKD and ESRD. The clinical manifestations of SLE as 
well as lupus nephritis [LN] in children are highly variable 
and can simulate both acute and chronic GN at its onset. LN 
often needs to be considered in the differential diagnosis of 
acute nephritic syndrome and nephritic-nephrotic clinical 
presentation. 
Epidemiology 
 LN can be either the presenting manifestation, or 
becomes evident at initial discovery of the disease in 60-80% 
of children [113-115]. In general, SLE as well as LN are 
more common in females. The disease is reported to be more 
prevalent in Asian and African American girls, as compared 
to Caucasians [116]. American College of Rheumatology 
[ACR] criteria for diagnosis of LN are: 1] persistent 
proteinuria defined as 0.5 g per day in a 24 hour urine 
collection or first morning spot urine protein/creatinine ratio 
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of 0.5] nephritic urine sediment consisting of red blood cells 
[RBCs], granular, tubular, or mixed casts. 3] Serologic 
diagnostic criteria of SLE, and 4] suggestive renal biopsy, 
when available [117]. Presence of renal failure is not 
included as a diagnostic criterion of LN in the current ACR 
definition. 
Pathogenesis 
 SLE is characterized by a disordered immune system, 
wherein auto-antibodies are produced against numerous 
“self” antigens, such as native DNA, cytoplasmic proteins 
and nuclear proteins. The auto-antibodies, in turn, form 
circulating and in-situ immune complexes that result in 
inflammatory response in the affected tissues and organs. 
Within the kidney, immune complex deposition, and 
subsequent inflammatory response can affect the glomeruli, 
tubulointerstitial space, as well as the vascular structures. 
Variable involvement of these tissue compartments by the 
inflammatory response and damage is common in patients 
with LN. 
Renal Pathology 
 The type of morphologic lesions encountered in LN is 
also diverse, ranging from almost normal glomeruli with 
mild mesangial proliferation to severe and diffusely 
proliferative GN. World Health Organization [WHO] 
provided a clinically relevant classification system for LN 
(Table 4) that has now been modified and enhanced by the 
International Society of Nephrology and the Renal Pathology 
Society [118]. 
 Immunofluorescence microscopy in LN usually 
demonstrates presence of immunoglobulins IgG, IgA and 
IgM, along with complement components, often referred to 
as “ full-house” immune deposition. Apart from the above 
noted lesions, renal biopsy may also show tubulointerstitial 
inflammation and fibrosis, presence of variable degrees of 
extra-glomerular cellular crescents and reticular structures 
Clinical Manifestations 
 Manifestations of LN are varied, and can be microscopic 
or gross hematuria, along with proteinuria. Nephritic-
nephrotic clinical features, with edema, hematuria, acute 
renal injury and hypertension are also commonly 
encountered. Patients with class V [Membranous variant] 
form of LN have heavy proteinuria and nephrotic syndrome 
as a dominant clinical finding. On the other hand, class III 
[diffuse proliferative] may have a nephritic-nephrotic 
presentation with hematuria-proteinuria, hypertension and 
elevated serum creatinine level. In an Italian registry of SLE 
nephritis, nephrotic syndrome, hypertension, and renal 
failure were present at onset in 40%, 28%, and 32%, 
respectively [119]. 
Diagnosis 
 Apart from studies to establish the diagnosis of SLE by 
various antibody titers and inflammatory markers, renal 
biopsy is essential in establishing the diagnosis of LN. 
Clinical features, urinary protein extcetion and urinary 
sediment evaluation may not provide sufficient evidence to 
diagnose LN in many patients, and “silent” LN has been well 
documented [120]. 
Treatment 
 Treatment of LN is largely dictated by the type of 
pathology seen on renal biopsy and the severity of the 
disease. Class I and II LN, which represent mild form of 
nephritis, is usually treated with corticosteroids to control of 
systemic disease. On the other hand, class III [focal 
proliferative LN] and class IV [diffuse proliferative LN] can 
be quite aggressive in their clinical course and carry a 
potential of adverse long term renal outcome, such as CKD 
and ESRD. For this reason, children affected by these classes 
of renal pathology need aggressive immunosuppression. 
Although numerous immunosuppressive options are now 
available for treatment of class III and IV LN, inravenous 
cyclophosphamide and MMF have emerged as the two 
primary induction therapies in children in a recent consensus 
statement [121]. 
 Intravenous cyclophosphamide induction consists of 
administering a total of six monthly doses, initiated at 500 
mg/m2 body surface area. Subsequent doses can be increased 
but not to exceed a maximum monthly dose of 1,500 mg 
[121]. MMF induction is dosed at 600 mg/m2/dose twice 
Table 4. Original World Health Organization [WHO] classification of lupus nephritis. Modified from: Churg J, Sobin LH: Renal 
Disease: Classification and Atlas of Glomerular Disease, Tokyo, Igaku-Shoin, 1982. 
 
Pathologic Class Renal Morphology 
Class I Normal glomeruli: but immune deposits are noted by immunofluorescence and electron microscopy 
Class II 
Mesangial alterations only 
a) No mesangial hypercellularity, but mesangial immune deposits are seen 
b) Mesangial matrix and cellular hypertrophy with immune deposits 
Class III Focal, proliferative glomerulonephritis: <50% glomeruli affected. 
Class IV Diffuse glomerulonephritis: >50% glomeruli affected. Severe mesangial, endocapillary, or mesangio-capillary proliferation and/or extensive subendothelial deposits] 
Class V Membranous glomerulonephritis 
Class VI Advanced glomerulosclerisis 
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daily, with a maximum dose of 1,500 mg taken two times per 
day. Mycophenolate sodium [MPA; Myfortic®] may be used 
as an alternative to MMF at a dose of 400 mg/m2/dose twice 
daily and maximum dose of 1,080 mg twice daily. It is 
important to monitor and prevent side effects, especially 
bone marrow suppression and infection risks associated with 
the immunosuppressive therapies [121, 122]. 
 Immunosuppressive drug dose should be adjusted to the 
nadir white blood cell count. Extra-renal manifestations and 
the activity level of the disease should also be monitored 
during induction therapy. Glucocorticosteroids are often 
prescribed at modest doses during induction of LN. Total 
duration of induction regimens lasts 6 months, after which 
the patients are gradually returned to a maintenance schedule 
of either corticosteroids alone, or in combination with MMF. 
 The treatment of choice for class V [membranous 
nephritis] LN is with calcineurin inhibitor agents, such as 
cyclosporine, since they respond less favorably to 
corticosteroids and cyclophosphamide. Austin et al. 
demonstrated that at 1 year, the cumulative probability of 
remission was 27% with prednisone, 60% with intravenous 
cyclophosphamide and 83% with cyclosporine [123]. Data 
on the use of tacrolimus in LN is scant. 
Prognosis 
 A decreasing trend of mortality of patients hospitalized 
with LN has been noted between the years of 2000-2009, and 
stands at 0.6% [124]. Progression of LN to CKD and ESRD 
is well documented. LN accounts for 5.8-6.4% of pediatric 
ESRD patients in the United States [125]. Renal survival was 
noted to be 44.4% at 5 years and 29% at 10 years between 
1965 and 1992 [126]. Poorer renal outcome and progression 
to ESRD is often associated with class III and IV 
[proliferative nephritis] LN [126, 127]. 
CONCLUDING REMARKS 
 GN is one of the common acquired pediatric renal 
disorders encountered in clinical practice. Resurgence of 
post-streptococcal GN since 1990s has made this to be the 
most common type of glomerulonephritis encountered, 
globally. Most chronic types of glomerulonephritidies 
manifest as nephrotic syndrome, or with a mixed nephritic-
nephrotic clinical picture. A better understanding of some 
forms of chronic types of GN is emerging with a more clear 
understanding of the physiology of podocytes. Several of 
these disorders are now believed to arise from dysfunctions 
of podocytes and are beginning to be grouped under the 
heading of “podocytopathies”. Other developments in this 
area relate to development of newer drugs that target 
complement dysfunction in clinical conditions, such as 
membranoproliferative GN. Genetic studies are also bound 
to provide another crucial link to the pathogenesis of GN in 
the future. 
ABBREVIATIONS 
APSGN = Acute post-streptococcal glomerulonephritis 
ASO = Anti-streptolysin O titer 
CKD = Chronic kidney disease 
ESRD = End stage renal disease 
GN = Glomerulonephritis 
HSP = Henoch-Schönlein purpura 
IgAN = IgA nephropathy 
LN = Lupus nephritis 
MMF = Mycophenolate mofetil 
RPGN = Rapidly progressive glomerulonephritis 
SLE = Systemic lupus erythematosis 
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